The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI), part of the National Institutes of Health.
Abecma sales disappoint again as BCMA competition ramps up, FDA adcomm looms
Fourth-quarter US sales of Bristol Myers Squibb’s BCMA-targeting CAR-T therapy Abecma last year declined by 40% compared to the same period in 2022, primarily due
February 3, 2024